Starting a thread of my clinical papers, similar to my previous threads of global oncology and cancer policy papers. Actually, my first peer reviewed paper was a clinical paper: a review on managing opioid induced constipation. 2015. https://www.tandfonline.com/doi/full/10.3109/00365521.2015.1054423">https://www.tandfonline.com/doi/full/...
We then published a case report of using pazopanib for orbital granular cell tumor https://www.spandidos-publications.com/10.3892/ol.2015.3263">https://www.spandidos-publications.com/10.3892/o...
While I was in Japan, I also did some work on #sarcopenia in cancer patients. Not very high quality stuff, but I was taking baby steps in clinical research. https://www.spandidos-publications.com/10.3892/mco.2016.1015">https://www.spandidos-publications.com/10.3892/m...
Another work on #sarcopenia investigating its prognostic role on patients with metastatic gastric cancer. https://www.spandidos-publications.com/10.3892/or.2015.4475">https://www.spandidos-publications.com/10.3892/o...
We routinely prescribe prophylactic laxatives while starting patients on opioids. But should we also routinely prescribe antiemetics? We did a survey of Japanese physicians. https://www.liebertpub.com/doi/10.1089/jpm.2015.0203">https://www.liebertpub.com/doi/10.10... cc @DeiselKain
Based on the results of this survey, we launched a double blind, placebo controlled RCT of prophylactic prochlorperazine for opioid induced N&V. https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2017-0225">https://theoncologist.onlinelibrary.wiley.com/doi/full/... #supportivecare
In 2016 in @CHematology , we reviewed the evidence for intermittent versus continuous docetaxel in mCRPC. #ProstateCancer https://www.sciencedirect.com/science/article/abs/pii/S1040842816300919">https://www.sciencedirect.com/science/a...
We also reviewed the evidence for treatment of locally advanced head and neck cancer. https://www.cancertreatmentreviews.com/article/S0305-7372(16)00010-4/abstract">https://www.cancertreatmentreviews.com/article/S... @KAZ99081
In this work led by @Poudyalbishesh again, we explored the safety and efficacy of azathioprine as 2L treatment for primary ITP. http://jnma.com.np/jnma/index.php/jnma/article/view/2832">https://jnma.com.np/jnma/inde...
And once upon a time, we compared outcomes of haplo vs allo transplant https://abs.twimg.com/emoji/v2/... draggable="false" alt="😉" title="Zwinkerndes Gesicht" aria-label="Emoji: Zwinkerndes Gesicht"> https://www.futuremedicine.com/doi/10.2217/fon-2016-0443">https://www.futuremedicine.com/doi/10.22...
In another paper @Annals_Oncology , we pooled the results from ASSURE and S-TRAC. I hope nobody is using adjuvant sunitinib in RCC anymore. @Ron_cology https://www.annalsofoncology.org/article/S0923-7534(19)32047-2/fulltext">https://www.annalsofoncology.org/article/S...
During oncology training, we learn this like a mantra: squamous NSCLC cis-gem but nonsquamous NSCLC cis-peme. How strong do you think is the evidence behind this? I learned a lot working on this @JAMAOnc paper with @VPrasadMDMPH https://jamanetwork.com/journals/jamaoncology/fullarticle/2645853">https://jamanetwork.com/journals/...
Also, @sarojniraula and I conducted a trial level meta analysis to test whether a shorter course of adjuvant trastuzuamb was non inferior to 1 year for HER2 positive breast cancer. The results were not what we had hoped for. https://www.cancertreatmentreviews.com/article/S0305-7372(17)30124-X/abstract">https://www.cancertreatmentreviews.com/article/S...
The title says it all. Learned a lot from @JackWestMD by working on this piece. https://jamanetwork.com/journals/jamaoncology/fullarticle/2705603">https://jamanetwork.com/journals/...
You can follow @oncology_bg.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: